← Browse by Condition
Medical Condition
recurrent acute myeloid leukemia
Total Trials
5
Recruiting Now
5
Trial Phases
Phase 1, Phase 2, Phase 1, Phase 2
NCT03471260 Phase 1, Phase 2
Recruiting
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
Enrollment
96 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
NCT06928662 Phase 1, Phase 2
Recruiting
Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
Enrollment
36 pts
Location
United States
Sponsor
Fred Hutchinson Cancer Center
NCT06222580 Phase 1
Recruiting
SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation
Enrollment
30 pts
Location
United States
Sponsor
Uma Borate
NCT04375631 Phase 1
Recruiting
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
Enrollment
120 pts
Location
United States
Sponsor
Fred Hutchinson Cancer Center
NCT02115295 Phase 2
Recruiting
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
Enrollment
508 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center